etrolizumab
Roche’s entrolizumab disappoints at Phase 3 in moderately to severely active ulcerative colitis
August 11, 2020Manufacturing and Production, Research and Development Roche, etrolizumab, trial failure, ulcerative colitis
Roche has voiced its disappointment after its investigational therapy etrolizumab showed “mixed results” as a treatment for moderately to severely …
Latest content
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
